Nuwellis, Inc.

🌟 Transforming Patient Care: A Success Story with Aquadex SmartFlow 🌟 Systemedic recently showcased the transformative potential of the Aquadex SmartFlow system at a leading hospital in Israel. A patient battling severe heart failure experienced significant improvements within just days of using this advanced ultrafiltration technology.   🔹 Fluid Reduction: 8 liters in 4 days, 20 liters in 7 days  🔹 Improved Kidney Function: Creatinine levels decreased from 2.5 mg/dL to 1.4 mg/dL  🔹 Enhanced Respiratory Function: Reduced need for oxygen support   Aquadex SmartFlow is designed to effectively manage fluid overload while maintaining electrolyte balance, offering a lifeline to those unresponsive to traditional treatments. This case underscores the profound impact innovative solutions like Aquadex can have on quality of life and healthcare outcomes. #nuwellis #aquadex

We’re proud to share that Nuwellis has partnered with a top-ranked pediatric hospital in Utah to utilize our Aquadex SmartFlow® system, enhancing care for children with severe kidney and heart conditions. This is our 44th pediatric hospital to date. This announcement exemplifies how Nuwellis continues to expand our reach to pediatric hospitals across the country. Learn more about our impact and future goals. https://lnkd.in/gxNKVPWb #PediatricCare #HealthcareInnovation #Nuwellis

🌟 Nuwellis is thrilled to be at the JP Morgan Healthcare Conference, starting today! 🏥💡 This premier event unites global leaders and innovative minds from across the healthcare sector. We’re excited to explore new trends, connect with industry experts, and gain insights that will enhance our cutting-edge fluid management solutions and improve patient care. Look forward to our reflections on the key learnings and opportunities post-conference! #JPMHC23 #HealthcareInnovation #Nuwellis #PatientCare

As the holiday season unfolds, we're filled with gratitude for our dedicated team and invaluable partners. Together, we've supported approximately 4,500 patients across nearly 140 medical teams in 2024 alone. This collective effort reminds us of the impact we can make when we unite in our mission. Thank you for being an essential part of our journey. Wishing everyone a joyful and prosperous holiday season! 🌟✨

Aquadex ultrafiltration therapy is transforming cardiac care by effectively managing post-operative fluid overload, which reduces complications with no additional ICU staff needed—key factors in cutting healthcare costs. How has integrating Aquadex impacted your clinical outcomes? Join the discussion and share your experiences. #CardiacCare #HealthcareEconomics #Aquadex #Nuwellis

Experience the impact of advanced fluid management in critical care through Fernando’s recovery journey. Research confirms that ultrafiltration technology significantly shortens ICU stays and lowers readmission rates, ensuring patients like Fernando receive the best care possible. Watch Fernando's journey and discover how Aquadex is transforming outcomes. https://lnkd.in/gCU4zADr #Nuwellis

At Nuwellis, you can make a difference. Our culture is driven by transforming the lives of patients suffering from fluid overload. Join us today!   Nuwellis, Inc. - Job Opportunities: https://lnkd.in/gEb5gdmC #nuwellis

Precision matters in critical care recovery. Aquadex delivers predictable, safe fluid removal to help support post-surgery recovery and manage kidney injury risk. Trusted by cardiac surgery and ICU teams, Aquadex is redefining patient care when traditional methods fall short. Discover how Aquadex can transform outcomes. www.nuwellis.com

Exciting news from Nuwellis! The Centers for Medicare and Medicaid (CMS) assigned Aquadex ultrafiltration therapy to Ambulatory Payment Classification (APC) 5242. Reimbursement rate for outpatient therapy to increase from $413 to $1,639 per day, effective January 1, 2025. “This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” said Nestor Jaramillo, President and CEO of Nuwellis. Read the full press release: https://lnkd.in/g98ASeX5

https://lnkd.in/gHbJxVgG #NuwellisNews: A newly published study demonstrates the effectiveness of #Aquadex in reducing 60-day hospital readmission rates for patients with acutely decompensated heart failure (ADHF) who are otherwise resistant to diuretic treatment. The study, titled, “Outcomes of Ultrafiltration in community-based hospitals” sought to evaluate and validate the role of a newly implemented Aquadex #ultrafiltration therapy program in a community hospital setting. Read the full press release for more about this new #ClinicalData. #HeartFailure #Ultrafiltration #MedTech